Pivotal Therapeutics Inc. recently announced encouraging top line data from the REVEAL study (n=110) on its cardiovascular candidate Vascazen in the US. Vascazen was successful in achieving the primary objective of the study of correcting Omega-3 deficiency.
Results from the study also revealed that Vascazen gained statistical significance in several other secondary objectives in patients having elevated triglycerides. The REVEAL trial is a randomized, double blind, placebo controlled, multi-center study. Pivotal Therapeutics enrolled 110 patients for the study.
The study evaluated the effects of Vascazen in the correction of Omega-3 deficiency in patients suffering from cardiovascular disease and having one or more risk factors associated with it. Moreover, the concomitant effects of Vascazen on cardiovascular risk factors including triglycerides, very-low-density lipoprotein (VLDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol among others, were also evaluated.
Pivotal Therapeutics stated in its press release that the positive top line data from the REVEAL study on Vascazen has been accepted for presentation at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions (ATVB).
We note that the cardiovascular market currently includes big players like Roche Holding (RHHBY - Free Report) and Sanofi (SNY - Free Report) .
We note that Vascazen is the lead product at Pivotal Therapeutics. Vascazen is formulated to meet the dietary Omega-3 deficient needs of patients suffering from cardiovascular diseases.
Pivotal Therapeutics currently carries a Zacks Rank #3 (Hold). Meanwhile other speciality pharmaceutical companies such as Biodel Inc. currently look better positioned. Biodel carries a Zacks Rank #2 (Buy).